GSK Approaches $1 Billion Acquisition of Biotech Firm IDRX: A Strategic Move in the Pharma Landscape

GlaxoSmithKline (GSK) is reportedly in the final stages of negotiating a significant deal valued at around $1 billion to acquire the biotech company IDRX. This development signifies a substantial strategic maneuver within the pharmaceutical sector, as GSK aims to enhance its portfolio of drugs and expand its presence in the biotechnology landscape.

Continue reading